Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04033302 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jun 1, 2026 to Dec 31, 2026
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Study description expanded, about 66 words
    • Site details revised
    v4
  2. Primary completion date: Jul 31, 2021 to Dec 31, 2029
    • Start date: Sep 1, 2019 to Jun 1, 2026
    • Study completion date: Dec 31, 2023 to Dec 31, 2030
    • Site contact updated
    v3
  3. Start date changed from estimate of Aug 1, 2019 to Sep 1, 2019v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cell therapy against CD7-positive hematological malignancies using CD7 specific CAR T cells. The study also aims to learn more about the function of CD7 CAR T cells and their persistence in patients of hematological malignancies.
Trial Details
NCT Number NCT04033302
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions
(from sponsor)		 T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma
Related terms Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov